News

Expert Outlines Drug-Development Obstacles in Lupus


 

Disclosures: Dr. Merrill has served as a consultant and clinical trialist for Genentech/Roche, Bristol-Myers Squibb Co., MedImmune Inc., and Human Genome Sciences; she has been a consultant for Amgen Inc., UCB Pharma Inc., and Serono Inc.; and she has received grants from Aspreva/Vifor and Wyeth/Pfizer for investigator-initiated studies.

In lupus, 'targeted therapies can only work if you know what you're targeting, in whom, and why.'

Source DR. MERRILL

Pages

Recommended Reading

CVD May Be Linked to Depression in Lupus
MDedge Rheumatology
Bosentan May Reduce Sclerotic Skin Fibrosis
MDedge Rheumatology
Clonal T Cells Role Held Key In Scleroderma
MDedge Rheumatology
Index Measures Partial Improvement in SLE
MDedge Rheumatology
Delaying Ambrisentan Cuts Long-Term Lung Capacity
MDedge Rheumatology
Oral Imatinib Shows Promise for Pulmonary Arterial Hypertension
MDedge Rheumatology
Vasoreactivity Testing a Must in Idiopathic PAH : Oral calcium channel blockers have no place in this testing, warns an ACC/AHA consensus statement.
MDedge Rheumatology
Clinically Quiescent Lupus Does Not Progress
MDedge Rheumatology
ACP Report: Support Family Caregivers
MDedge Rheumatology
Hallucinations Common in Pediatric Lupus
MDedge Rheumatology